



## MONTHLY MORBIDITY REPORT

PUBLIC HEALTH STATISTICS and  
DIVISION OF DISEASE CONTROL

DEPARTMENT OF HEALTH AND HUMAN RESOURCES  
OFFICE OF PREVENTIVE AND PUBLIC HEALTH SERVICES  
P.O. BOX 60630, NEW ORLEANS, LOUISIANA 70160

SANDRA L. ROBINSON, M.D., M.P.H.  
SECRETARY AND STATE HEALTH OFFICER  
504/342-6711

Recommendation of the Immunization  
Practices Advisory Committee (ACIP)

**Polysaccharide Vaccine for Prevention \*  
of *Haemophilus influenzae* Type b Disease**

**INTRODUCTION**

A polysaccharide vaccine\* against invasive (bacteremic) disease caused by *Haemophilus influenzae* type b recently has been licensed in the United States. The purposes of this statement are to summarize available information about this vaccine and to offer guidelines for its use in the prevention of invasive *H. influenzae* type b disease.

**HAEMOPHILUS INFLUENZAE DISEASE**

*H. influenzae* is a leading cause of serious systemic bacterial disease in the United States. It is the most common cause of bacterial meningitis, accounting for an estimated 12,000 cases annually, primarily among children under 5 years of age. The mortality rate is 5%, and neurologic sequelae are observed in as many as 25%-35% of survivors. Virtually all cases of *H. influenzae* meningitis among children are caused by strains of type b (Hib), although this capsular type represents only one of the six types known for this species. In addition to bacterial meningitis, Hib is responsible for other invasive diseases, including epiglottitis, sepsis, cellulitis, septic arthritis, osteomyelitis, pericarditis, and pneumonia. Nontypeable (noncapsulated) strains of *H. influenzae* commonly colonize the human respiratory tract and are a major cause of otitis media and respiratory mucosal infection but rarely result in bacteremic disease. Hib strains account for only 5%-10% of *H. influenzae* causing otitis media.

Several population-based studies of invasive Hib disease conducted within the last 10 years have provided estimates of the incidence of disease among children under 5 years of age, the major age group at risk. These studies have demonstrated attack rates of meningitis ranging from 51 cases per 100,000 children to 77/100,000 per year and attack rates of other invasive Hib disease varying from 24/100,000 to 75/100,000 per year (1). Thus, in the United States, approximately one of every 1,000 children under 5 years of age develops systemic Hib disease each year, and a child's cumulative risk of developing systemic Hib disease at some time during the first 5 years of life is about one in 200. Attack rates peak between 6 months and 1 year of age and decline thereafter. Approximately 35%-40% of Hib disease occurs among children 18 months of age or older, and 25% occurs above 24 months of age.

Incidence rates of Hib disease are increased in certain high-risk groups, such as Native Americans (both American Indians and Eskimos), blacks, individuals of lower socioeconomic status, and patients with asplenia, sickle cell disease, Hodgkin's disease, and antibody deficiency syndromes. Recent studies also have suggested that the risk of acquiring primary Hib disease for children under 5 years of age appears to be greater for those who attend day-care facilities than for those who do not (2,3).

\*Official name: Haemophilus b Polysaccharide Vaccine.

\* Reprint from MMWR, Centers for Disease Control, April 19, 1985, Vol. 34, No. 15, pp. 201-205.

*ACIP: Haemophilus b Polysaccharide Vaccine – Continued*

The potential for person-to-person transmission of systemic Hib disease among susceptible individuals has been recognized in the past decade. Studies of secondary spread of Hib disease in household contacts of index patients have shown a substantially increased risk of disease among exposed household contacts under 4 years of age (4). In addition, numerous clusters of cases in day-care facilities have been reported, and recent studies suggest that secondary attack rates in day-care classroom contacts of a primary case also may be increased (5,6).

**HAEMOPHILUS b POLYSACCHARIDE VACCINE**

The Hib vaccine is composed of the purified, capsular polysaccharide of *H. influenzae* type b ([ $\rightarrow$ 3] ribose- $\beta$ 1  $\rightarrow$ 1 ribitol-1 phosphate-5 $\rightarrow$ ). Antibodies to this antigen correlate with protection against invasive disease. The Hib vaccine induces an antibody response that is directly related to the age of the recipient; infants respond infrequently and with less antibody than do older children or adults (7). Improved responses are observed by 18 months of age, although children 18-23 months of age do not respond as well as those 2 years of age or older. The frequency and magnitude of antibody responses reach adult levels at about 6 years of age (8,9). Levels of antibodies to the capsular polysaccharide also decline more rapidly in immunized infants and young children than in adults.

In a manner similar to other polysaccharide antigens, revaccination with Hib vaccine results in a level of antibody comparable to that for a child of the same age receiving a first immunization (10). Such polysaccharide antigens have been termed "T-cell independent" because of their failure to induce the T-cell memory response characteristic of protein antigens.

Limited data are available on the response to Hib vaccine in high-risk groups with underlying disease. By analogy to pneumococcal vaccine, patients with sickle cell disease or asplenia are likely to exhibit an immune response to the Hib vaccine. Patients with malignancies associated with immunosuppression appear to respond less well. Additional data on the immune response to Hib vaccine in these groups are needed.

A precise protective level of antibody has not been established. However, based on evidence from passive protection in the infant rat model and from experience with agammaglobulinemic children, an antibody concentration of 0.15  $\mu$ g/ml correlates with protection (7,8,11). In the Finnish field trial, levels of capsular antibody greater than 1  $\mu$ g/ml in 3-week postimmunization sera correlated with clinical protection for a minimum of 1½ years (9,12,13). Approximately 75% of children 18-23 months of age tested achieved a level greater than 1  $\mu$ g/ml, as did 90% of 24-35 month old children (9). Measurement of Hib antibody levels is not routinely available, however, and determination of antibody levels following vaccination is not indicated in the usual clinical setting.

**EFFECTIVENESS OF VACCINE**

In 1974, a randomized, controlled trial of clinical efficacy was conducted in Finland among children 3-71 months of age (9). Approximately 98,000 children, half of whom received the Hib vaccine, were enrolled in the field trial and followed for a 4-year period for occurrence of Hib disease. Among children 18-71 months of age, 90% protective efficacy (95% confidence limits, 55%-98%) in prevention of all forms of invasive Hib disease was demonstrated for the 4-year follow-up period. Although no disease occurred among over 4,000 children 18-23 months of age immunized with Hib vaccine and followed for 4 years, only two cases occurred in the control vaccine recipients in this age group. As a result, vaccine efficacy in the subgroup of children immunized at 18-23 months of age could not be evaluated statistically. The vaccine was not efficacious in children under 18 months of age.

**REVACCINATION**

Limited data regarding the potential need for revaccination are available at present. Current data show that children who have received the Hib vaccine 2-42 months previously have an immune response to the vaccine similar to that in previously unvaccinated children of the

*ACIP: Haemophilus b Polysaccharide Vaccine – Continued*

same age. No immunologic tolerance or impairment of immune response to a subsequent dose of vaccine occurs (10). As with other polysaccharide vaccines, the shorter persistence of serum antibodies in young children given Hib vaccine, compared with adults, suggests that a second dose of vaccine may be needed to maintain immunity throughout the period of risk, particularly for children in the youngest age group considered for vaccination (those 18-23 months of age). A second injection following the initial dose is likely to increase the protective benefit of vaccination for this high-risk group, because antibody titers 18 months after vaccination, although detectable in most vaccine recipients, are no longer significantly different from those in unvaccinated children of the same age.

**RECOMMENDATIONS FOR VACCINE USE**

Recently published data regarding vaccine efficacy and the risk of Hib disease among young children strongly support the use of Hib vaccine in the United States in high-risk persons for whom efficacy has been established. Specific recommendations are as follows:

1. **Immunization of all children at 24 months of age is recommended.** The precise duration of immunity conferred by a single dose of Hib vaccine at 24 months of age is not known, although, based on available data, protection is expected to last 1½-3½ years. Until further data are available to determine whether an additional dose of vaccine may be necessary to ensure long-lasting immunity, routine revaccination is not recommended.
2. **Immunization of children at 18 months of age, particularly those in known high-risk groups, may be considered.** Although the precise efficacy of the vaccine among children 18-23 months of age is not known, this age group accounts for approximately 12% of all invasive Hib disease among children under 5 years of age, and Hib vaccine has been shown by serologic methods to be immunogenic in most children of this age group. However, physicians and parents should be informed that the vaccine is not likely to be as effective in this age group as in older children. These younger children may need a second dose of vaccine within 18 months following the initial dose to ensure protection. Additional data regarding the duration of the antibody response are needed to define the timing of a second dose more precisely.

Children who attend day-care facilities are at particular risk of acquiring systemic Hib disease. Initial vaccination at 18 months of age for this high-risk group should be considered.

Children with chronic conditions known to be associated with increased risk for Hib disease should receive the vaccine, although only limited data on immunogenicity and clinical efficacy in this group are available. These conditions include anatomic or functional asplenia, such as sickle cell disease or splenectomy (14), and malignancies associated with immunosuppression (15).

3. **Immunization of individuals over 24 months of age who have not yet received Hib vaccine should be based on risk of disease.** The risk of invasive Hib disease decreases with increasing age over the age of 2 years. Because the vaccine is safe and effective, however, physicians may wish to immunize previously unvaccinated healthy children between 2 years and 5 years of age to prevent the Hib disease that does occur in this age group. The potential benefit of this strategy in terms of cases prevented declines with increasing age of the child at the time of vaccination. Therefore, children 2-3 years of age who attend day-care facilities should be given a higher priority than day-care attendees who are 4-5 years old.
4. **Insufficient data are available on which to base a recommendation concerning use of the vaccine in older children and adults with the chronic conditions associated with an increased risk of Hib disease.**
5. **Vaccine is not recommended for children under 18 months of age.**

6. Simultaneous administration of Hib and DTP vaccines at separate sites can be performed, because no impairment of the immune response to the individual antigens occurs under these circumstances.

#### SIDE EFFECTS AND ADVERSE REACTIONS

Polysaccharide vaccines are among the safest of all vaccine products. To date, over 60,000 doses of the Hib polysaccharide vaccine have been administered to infants and children, and several hundred doses have been given to adults (9, 16). Only one serious systemic reaction has been reported thus far—a possible anaphylactic reaction that responded promptly to epinephrine. High fever (38.5 C [101.3 F] or higher) has been reported in fewer than 1% of Hib vaccine recipients. Mild local and febrile reactions were common, occurring in as many as half of vaccinated individuals in the Finnish trial. Such reactions appeared within 24 hours and rapidly subsided. Current preparations appear to result in fewer such local reactions. Simultaneous administration with DTP does not result in reaction rates above those expected with separate administration (17).

#### PRECAUTIONS AND CONTRAINDICATIONS

The Hib vaccine is unlikely to be of substantial benefit in preventing the occurrence of secondary cases, because children under 2 years old are at highest risk of secondary disease. Because the vaccine will not protect against nontypeable strains of *H. influenzae*, recurrent upper respiratory diseases, including otitis media and sinusitis, are not considered indications for vaccination.

#### NEW VACCINE DEVELOPMENT

New vaccines, such as the Hib polysaccharide-protein conjugate vaccines, are being developed and evaluated and may prove to be efficacious for children under 18 months of age.

#### References

1. Cochi SL, Broome CV, Hightower AW. Immunization of US children with *Hemophilus influenzae* type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment. *JAMA* 1985;253:521-9.
2. Istre GR, Conner JS, Broome CV, Hightower A, Hopkins RS. Risk factors for primary invasive *Haemophilus influenzae* disease. Increased risk from day care attendance and school-aged household members. *J Pediatr* 1985;106:190-5.
3. Redmond SR, Pichichero ME. *Haemophilus influenzae* type b disease. An epidemiologic study with special reference to day-care centers. *JAMA* 1984;252:2581-4.
4. CDC. Prevention of secondary cases of *Haemophilus influenzae* type b disease. *MMWR* 1982;31:672-80.
5. Murphy TV, Breedlove JA, Fritz EH, Sebestyen DM, Hansen EJ. County-wide surveillance of invasive *Haemophilus* infections: risk of associated cases in child care programs (CCPs). Twenty-third Interscience Conference on Antimicrobial Agents and Chemotherapy 1983;229 (abstract #788).
6. Fleming D, Leibenhaut M, Albanes D, et al. *Haemophilus influenzae* b (Hib) disease—secondary spread in day care. Twenty-fourth International Conference on Antimicrobial Agents and Chemotherapy 1984;261 (abstract #967).
7. Smith DH, Peter G, Ingram DL, Harding AL, Anderson P. Responses of children immunized with the capsular polysaccharide of *Hemophilus influenzae*, type b. *Pediatrics* 1973;52:637-44.
8. Robbins JB, Parke JC Jr, Schneerson R, Whisnant JK. Quantitative measurement of "natural" and immunization-induced *Haemophilus influenzae* type b capsular polysaccharide antibodies. *Pediatr Res* 1973;7:103-10.
9. Peltola H, Käyhty H, Virtanen M, Mäkelä PH. Prevention of *Hemophilus influenzae* type b bacteremic infections with the capsular polysaccharide vaccine. *N Engl J Med* 1984;310:1561-6.
10. Käyhty H, Karanko V, Peltola H, Mäkelä PH. Serum antibodies after vaccination with *Haemophilus influenzae* type b capsular polysaccharide and responses to reimmunization: no evidence of immunological tolerance or memory. *Pediatrics* 1984;74:857-65.
11. Robbins JB, Schneerson R, Parke JC Jr. A review of the efficacy trials with *Haemophilus influenzae* type b polysaccharide vaccines. In: Sell SH, Wright PF, eds. *Haemophilus influenzae*. New York: Elsevier Science Publishing Co., 1982:255-63.
12. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of *Haemophilus influenzae* type b. *J Infect Dis* 1983;147:1100.

(Continued on back cover)

## SELECTED REPORTABLE DISEASES (By Place of Residence)

STATE AND PARISH TOTALS	VACCINE PREVENTABLE DISEASES					ASEPTIC MENINGITIS	HEPATITIS A AND UNSPECIFIED**	HEPATITIS B	LEGIONELLOSIS	MALARIA***	MENINGOCOCCAL INFECTIONS	SHIGELLOSIS	TUBERCULOSIS, PULMONARY	TYPHOID FEVER	OTHER SALMONELLOSIS	UNDERNUTRITION SEVERE	GONORRHEA	SYPHILIS, PRIMARY AND SECONDARY	RABIES IN ANIMALS (PARISH TOTALS CUMULATIVE, 1984 )
	MEASLES	RUBELLA*	MUMPS	PERTUSSIS	TETANUS														
TOTAL TO DATE 1984	0	0	0	1	0	6	79	84	0	1	17	11	60	1	25	3	6669	323	7
TOTAL TO DATE 1985	0	0	0	1	0	12	29	44	0	0	13	7	72	0	27	2	6050	270	4
TOTAL THIS MONTH	0	0	0	1	0	5	12	26	0	0	9	3	22	0	14	2	1960	82	1
ACADIA											1						11		
ALLEN																	1		
ASCENSION																	12	1	
ASSUMPTION								1									2		
AVOUELLES																	5	1	2
BEAUREGARD																	7		
BIENVILLE							1					1					3		
BOSSIER												1					26		
CADDO							2			1		2		2			167	6	
CALCASIEU							1	1				2		2			82	2	
CALDWELL																			
CAMERON																			
CATAHOULA																	4	1	
CLAIBORNE															1		4		
CONCORDIA																	6		
DESOTO																			1
EAST BATON ROUGE						1		1				1		1			117	8	
EAST CARROLL																	9	2	
EAST FELICIANA												1					2		
EVANGELINE																	2		1
FRANKLIN																	2		
GRANT							1										4		
IBERIA								1		1							22	2	
IBERVILLE														1			6		
JACKSON																	10		
JEFFERSON								4		2		2		2			107	6	
JEFFERSON DAVIS																	10		
LAFAYETTE							1	3				1					65	2	
LAFOURCHE								1				1					1	2	
LASALLE																			
LINCOLN																	13		
LIVINGSTON						1				1	1			1					
MADISON																	11	1	
MOREHOUSE												1					20		
NATCHITOCHE																	5	2	
ORLEANS								6		1	2	2		1			757	30	
OUACHITA												2					84	3	
PLAQUEMINES																			
POINTE COUPEE																			
RAPIDES							3	3				1					89	6	
RED RIVER										1									
RICHLAND																1	9		
SABINE																			1
ST. BERNARD																	3		
ST. CHARLES																	12		
ST. HELENA																			
ST. JAMES																	9	1	
ST. JOHN								1									6		
ST. LANDRY								1				2		1			39	1	
ST. MARTIN																	3	1	
ST. MARY																	15		
ST. TAMMANY							1	1						3			17		
TANGIPAHOA										1							11		
TENSAS																	6		
TERREBONNE						2	1					1					26		
UNION																	3		
VERMILION				1													9		
VERNON								1									88		
WASHINGTON						1						1					12		
WEBSTER							1										21	2	
WEST BATON ROUGE								1											
WEST CARROLL																	3	1	
WEST FELICIANA																	1		
WINN																			
OUT OF STATE																	1		

\* Includes Rubella, Congenital Syndrome.

\*\* Includes 3 cases of Hepatitis Non A, and Non B.

\*\*\* Acquired outside United States unless otherwise stated.

From January 1, 1985 - March 31, 1985 the following cases were also reported:  
2-Reye Syndrome.

RAOULT C RAYARD MD  
4109 CLEVELAND PL  
METAIRIE LA 70003

8

BULK RATE  
U.S. POSTAGE  
PAID  
NEW ORLEANS, LA.  
PERMIT No. 471

DEPARTMENT OF HEALTH AND HUMAN RESOURCES  
OFFICE OF PREVENTIVE AND PUBLIC HEALTH SERVICES  
PUBLIC HEALTH STATISTICS

*ACIP: Haemophilus b Polysaccharide Vaccine — Continued from page 4*

13. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of *Haemophilus influenzae* type b [Letter]. *J Infect Dis* 1984;149:1034-5.
14. Ward J, Smith AL. *Haemophilus influenzae* bacteremia in children with sickle cell disease. *J Pediatr* 1976;88:261-3.
15. Siber GR. Bacteremias due to *Haemophilus influenzae* and *Streptococcus pneumoniae*: their occurrence and course in children with cancer. *Am J Dis Child* 1980;134:668-72.
16. Parke JC Jr, Schneerson R, Robbins JB, and Schlesselman JJ. Interim report of a controlled field trial of immunization with capsular polysaccharides of *Haemophilus influenzae* type b and group C *Neisseria meningitidis* in Mecklenburg County, North Carolina (March 1974-March 1976) *J Infect Dis* 1977;136:S51-6.
17. Lepow ML, Peter G, Glode MP, et al. Response of infants to *Haemophilus influenzae* type b polysaccharide and diphtheria-tetanus-pertussis vaccines in combination. *J Infect Dis* 1984;149:950-5.

This public document was published at a total cost of \$1405. 6200 copies of this public document were published in this first printing at a cost of \$475. This document was published for the Office of Preventive and Public Health Services by the Office of Management and Finance, Printing Operations, Baton Rouge, Louisiana to inform physicians, hospitals, and the public of current Louisiana morbidity status under authority of R.S. 40:36. This material was printed in accordance with the standards for printing by state agencies established pursuant to R.S. 43:31.